Cara Therapeutics Announces Positive Results From KALM-1 Pivotal Phase 3 Trial of KORSUVA™ Injection in Hemodialysis Patients with Pruritus

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. META
3. ABBV
4. SPY
5. FDX
6. IBM
7. MU
8. ACN
9. USO
10. NVDA

Go back to Cara Therapeutics Announces Positive Results From KALM-1 Pivotal Phase 3 Trial of KORSUVA™ Injection in Hemodialysis Patients with Pruritus

Stifel Reiterates Buy Rating on Cara Therapeutics (CARA)

May 29, 2019 8:23 AM EDT

Stifel analyst Annabel Samimy reiterated a Buy rating and $26.00 price target on Cara Therapeutics (NASDAQ: CARA) following positive top-line data from the first pivotal study (KALM-1) of IV-Korsuva in pruritus associated with chronic kidney disease (CKD-aP) in hemodialysis patients.

The study met its... More

Cara Therapeutics (CARA) to Resume Trading at 7:30 am ET

May 29, 2019 7:04 AM EDT

Cara Therapeutics (NASDAQ: CARA) to Resume Trading at 7:30 am ET

... More